Ingredia has acquired Galactis Pharma shares, a company specialising in bioactive peptides for the pharmaceutical industry.
“This acquisition is going to enable Ingredia to strengthen its position as a market leader in bioactive milk peptides by highlighting two of our recent patents,” said Matthieu Arguillère, CEO of Ingredia.
Bioactive peptides are natural milk components carrying a range of health benefits, as demonstrated by research. These are said to include digestive health, stress management and anti-microbial qualities. Other peptides display a cholesterol-lowering action, offer immuno-modulating properties, or facilitate minerals transportation. Unlike pharmaceutical molecules, they generally have no side effects.
After further clinical investigation, Ingredia believes that the acquisition of Galactis Pharma will allow it to expand its portfolio of bioactive ingredients focused on health benefits and also enter the pain management market. Ingredia Nutritional, one of the company’s business units, specialises in the development and marketing of natural and innovative bioactives. It operates in the health and nutrition industry and, through its portfolio of bioactive ingredients, specifically offers Lactium, which is described as a unique patented solution for the management of stress symptoms.
